exactsciences.com - EXAS Company Short-Term Debt

Exact Sciences Corporation (EXAS) - corporate logo

Exact Sciences management is focusing on achieving stable profitability and launching new products. On GURU.Markets, debt maturing within one year reflects current liquidity dynamics with a metric value of 0.00. The business relies on its leadership in non-invasive cancer screening via Cologuard, while its R&D center actively develops liquid biopsy systems for early tumor detection.

EXAS (Exact Sciences Corporation) Company Short-Term Debts history from 07/04/2022 to 04/04/2026

Exact Sciences Inc. - analytical breakdowns and key metrics (EXAS)

- price and consensus price forecast:
Stock Price Exact Sciences Corporation|EXAS - Analyst Consensus Forecast
- market capitalization data:
Market Value Exact Sciences Corporation|EXAS - Business Value
- book capitalization data:
Book Value per Share Exact Sciences|EXAS - Book Capitalization|Market Value to Book Value Ratio exactsciences.com|EXAS - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Exact Sciences|EXAS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Exact Sciences|EXAS - Company Total Debt Obligations|Debts to Book Capitalization Exact Sciences Corporation|EXAS - Long-Term Debt Volume|Company Short-Term Debt Exact Sciences
Analysis of all company metrics:Exact Sciences Corporation EXAS
Finished products of Exact Sciences

Short-term debt measures obligations due within the next operating cycle. This metric allows an investor to assess current liquidity and filter out market noise when analyzing solvency. The trend in borrowings with a maturity of up to one year reflects the risk of capital freezing. Reducing this burden is critical for Exact Sciences (EXAS), as the robotization of DNA screening requires stable financing. The high cost of AI infrastructure makes the control of short-term liabilities a guarantee of business sustainability.

Competitor analysis for Exact Sciences

Agilent - Company Short-Term Debts|DGX: Company Short-Term Debts|Company Short-Term Debt Illumina Corp|Revvity Corp (RVTY) - Company Short-Term Indebtedness|BIO (Bio-Rad Laboratories) - Company Short-Term Debts|Company Short-Term Debts NNNN|Company Short-Term Debt Sotera Health (SHC)|Company Short-Term Debt Quidel Corporation QDEL|OPK: Company Current Liabilities|CareDx - Short-Term Debt|Company Short-Term Debt MRVI (Maravai LifeSciences)|FLGT - Short-Term Debt Volume|Standard BioTools - Company Short-Term Debts|CTKB (Cytek Biosciences Inc) - Short-Term Debt Volume|OSUR: Company Short-Term Debt|Short-Term Debt Volume Exagen Diagnostics|MDxHealth SA - Company Short-Term Debts|Short-Term Debt luciddx.com LUCD|PRE - Company Current Liabilities|Company Short-Term Indebtedness Insight Molecular Diagnostics, Inc. IMDX|Trinity Biotech Corp - Company Short-Term Debts|PRPH - Company Short-Term Debts|AIMD (Ainos, Inc.) - Company Short-Term Debts|Company Current Liabilities codiagnostics.com|HeartSciences (HSCS) - Company Current Liabilities|Amount of Current Liabilities Biomerica Inc. (BMRA)|Cardio Diagnostics (CDIO) - Company Current Liabilities|Company Short-Term Loans and Borrowings VRAX (Virax Biolabs Corp)|Company Short-Term Debt BJDX|Short-Term Debt Volume aspirawh.com AWH|AXDX: Company Short-Term Debts|CNTG - Company Current Liabilities|enzo.com - Company Short-Term Debts|Fresh2 Group (FRES) - Short-Term Debt Volume|Company Short-Term Debts GENE (Genetic Technologies Ltd)|Short-Term Debt ME|Company Short-Term Debt Psychemedics Corporation PMD